Home
AMIX
AMIX News

Latest AUTONOMIX MEDICAL INC (AMIX) News on June 7, 2025

MT Newswires

2 days ago

Autonomix Medical Approved to Begin Testing Treatment for Cancer-Related Pain in Uzbekistan

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain

GlobeNewswire

2 days ago

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain

AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech

Zacks

16 days ago

AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology

GlobeNewswire

23 days ago

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology

Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event

GlobeNewswire

24 days ago

Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event

Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market

GlobeNewswire

25 days ago

Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market

Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain

GlobeNewswire

a month ago

Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain

GlobeNewswire

a month ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain

Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain

GlobeNewswire

a month ago

Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain

MT Newswires

a month ago

Maxim Group Initiates Coverage on Autonomix Medical With Buy Rating, $5 Price Target

Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR

GlobeNewswire

a month ago

Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology

GlobeNewswire

2 months ago

Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology

Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain

GlobeNewswire

2 months ago

Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain

Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)

GlobeNewswire

2 months ago

Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

3 months ago

Sector Update: Health Care Stocks Edge Higher Late Afternoon

MT Newswires

3 months ago

Sector Update: Health Care

MT Newswires

3 months ago

Autonomix Medical Granted US Patent for Catheter-Based Technology; Shares Up 10% Pre-Bell

Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company’s Proprietary Catheter-Based Technology

GlobeNewswire

3 months ago

Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company’s Proprietary Catheter-Based Technology

Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials in 2025 with Completed Integration of Apex 6 Generator for Transvascular Ablation

GlobeNewswire

3 months ago

Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials in 2025 with Completed Integration of Apex 6 Generator for Transvascular Ablation

Autonomix Medical, Inc. Announces Abstract Highlighting Technology and Early Proof-of-Concept Study Results Accepted at the Society of Interventional Radiology (SIR) Annual Scientific Meeting

GlobeNewswire

3 months ago

Autonomix Medical, Inc. Announces Abstract Highlighting Technology and Early Proof-of-Concept Study Results Accepted at the Society of Interventional Radiology (SIR) Annual Scientific Meeting

Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the LSI USA ’25 Emerging Medtech Summit

GlobeNewswire

3 months ago

Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the LSI USA ’25 Emerging Medtech Summit

Autonomix Medical, Inc. Selected for Podium Presentation at the 2025 CRT Annual Meeting

GlobeNewswire

4 months ago

Autonomix Medical, Inc. Selected for Podium Presentation at the 2025 CRT Annual Meeting

Autonomix Medical, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GlobeNewswire

4 months ago

Autonomix Medical, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Autonomix Medical, Inc. Reports Third Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update

GlobeNewswire

4 months ago

Autonomix Medical, Inc. Reports Third Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

GlobeNewswire

4 months ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025

GlobeNewswire

5 months ago

Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

GlobeNewswire

5 months ago

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

Autonomix Medical, Inc. Announces Abstract Highlighting Preliminary Positive Clinical Results Accepted at The Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting

GlobeNewswire

5 months ago

Autonomix Medical, Inc. Announces Abstract Highlighting Preliminary Positive Clinical Results Accepted at The Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting

Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company’s Proprietary Catheter-Based Technology

GlobeNewswire

5 months ago

Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company’s Proprietary Catheter-Based Technology

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

GlobeNewswire

5 months ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality

GlobeNewswire

6 months ago

Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality

Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025

GlobeNewswire

6 months ago

Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025

Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option

GlobeNewswire

6 months ago

Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option

Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering

GlobeNewswire

7 months ago

Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering

Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update

GlobeNewswire

7 months ago

Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update

Autonomix Medical, Inc. Reports New Positive Topline Results from First 15 Patients’ 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction

GlobeNewswire

7 months ago

Autonomix Medical, Inc. Reports New Positive Topline Results from First 15 Patients’ 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction

Autonomix Medical, Inc.’s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial

GlobeNewswire

7 months ago

Autonomix Medical, Inc.’s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial

Positive Preliminary Results Demonstrate Autonomix’s Proprietary RF Ablation Technology’s Ability to Reduce Opioid Use in Ongoing Human Clinical Trial

GlobeNewswire

7 months ago

Positive Preliminary Results Demonstrate Autonomix’s Proprietary RF Ablation Technology’s Ability to Reduce Opioid Use in Ongoing Human Clinical Trial

Autonomix Medical, Inc. to Participate in a Virtual Investor “What This Means” Segment on Wednesday, October 30th

GlobeNewswire

7 months ago

Autonomix Medical, Inc. to Participate in a Virtual Investor “What This Means” Segment on Wednesday, October 30th

Autonomix Announces Reverse Stock Split

GlobeNewswire

8 months ago

Autonomix Announces Reverse Stock Split

Autonomix Medical, Inc. to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC

GlobeNewswire

8 months ago

Autonomix Medical, Inc. to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC

This Company Is Taking An Innovative, Non-Opioid Approach To Pain Management For Pancreatic Cancer

ACCESSWIRE

8 months ago

This Company Is Taking An Innovative, Non-Opioid Approach To Pain Management For Pancreatic Cancer

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

GlobeNewswire

8 months ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

Autonomix Selected to Present at the 2024 Octane Medical Innovation Forum

GlobeNewswire

9 months ago

Autonomix Selected to Present at the 2024 Octane Medical Innovation Forum

Autonomix Announces 83% Reduction of Pain at 4-6 Week Follow-Up from Lead-In Patients in Ongoing Human Clinical Trial in Pancreatic Cancer Pain Patients

GlobeNewswire

9 months ago

Autonomix Announces 83% Reduction of Pain at 4-6 Week Follow-Up from Lead-In Patients in Ongoing Human Clinical Trial in Pancreatic Cancer Pain Patients

Autonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

9 months ago

Autonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference

Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual Congress

GlobeNewswire

10 months ago

Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual Congress

Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones

GlobeNewswire

10 months ago

Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

GlobeNewswire

10 months ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

Autonomix Completes Licensing Transaction for FDA-Cleared Ablation Technology

GlobeNewswire

10 months ago

Autonomix Completes Licensing Transaction for FDA-Cleared Ablation Technology

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

GlobeNewswire

a year ago

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Covering Technology License Agreement

GlobeNewswire

a year ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Covering Technology License Agreement

Autonomix's Trial Results Show Meaningful Reduction In Pain For Patients Suffering From Pancreatic Cancer

ACCESSWIRE

a year ago

Autonomix's Trial Results Show Meaningful Reduction In Pain For Patients Suffering From Pancreatic Cancer

Autonomix Enters into Definitive Agreement to License Intellectual Property for FDA-Cleared Ablation Technology from RF Innovations, Inc.

GlobeNewswire

a year ago

Autonomix Enters into Definitive Agreement to License Intellectual Property for FDA-Cleared Ablation Technology from RF Innovations, Inc.

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Launch of CEO Corner Platform

GlobeNewswire

a year ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Launch of CEO Corner Platform

Autonomix Medical, Inc. (NASDAQ: AMIX) Reviews Positive Results Seen in Pancreatic Cancer Pain Trial in Virtual Investor “What This Means” Segment

GlobeNewswire

a year ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Reviews Positive Results Seen in Pancreatic Cancer Pain Trial in Virtual Investor “What This Means” Segment

Autonomix Announces Positive Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial

GlobeNewswire

a year ago

Autonomix Announces Positive Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial

Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer

GlobeNewswire

a year ago

Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer

Autonomix to Announce Preliminary Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial on June 18, 2024

GlobeNewswire

a year ago

Autonomix to Announce Preliminary Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial on June 18, 2024

This One Company Is Working On A Breakthrough Approach To Revolutionize Pain Management

ACCESSWIRE

a year ago

This One Company Is Working On A Breakthrough Approach To Revolutionize Pain Management

Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial

GlobeNewswire

a year ago

Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial

Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update

Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer

GlobeNewswire

a year ago

Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

GlobeNewswire

a year ago

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

Autonomix Enters into Agreement with NoiseFigure Research, Inc. to Develop Next Generation of its Proprietary Microchip

GlobeNewswire

a year ago

Autonomix Enters into Agreement with NoiseFigure Research, Inc. to Develop Next Generation of its Proprietary Microchip

Autonomix to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

GlobeNewswire

a year ago

Autonomix to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain

GlobeNewswire

a year ago

Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

News Direct

a year ago

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation

GlobeNewswire

a year ago

Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation

Autonomix to Participate in the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker

GlobeNewswire

a year ago

Autonomix to Participate in the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker

Autonomix to Present at the MedInvest Biotech & Pharma Investor Conference

GlobeNewswire

a year ago

Autonomix to Present at the MedInvest Biotech & Pharma Investor Conference

Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024

GlobeNewswire

a year ago

Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024

Autonomix Appoints Jennifer Cook as Chief Business Officer

GlobeNewswire

a year ago

Autonomix Appoints Jennifer Cook as Chief Business Officer

Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

GlobeNewswire

a year ago

Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

GlobeNewswire

a year ago

Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial

GlobeNewswire

a year ago

Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity

GlobeNewswire

a year ago

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity

Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study

GlobeNewswire

a year ago

Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study

Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

GlobeNewswire

a year ago

Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones

GlobeNewswire

a year ago

Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones

ACCESSWIRE

a year ago

Autonomix Medical, Inc. (NASDAQ:AMIX) to Present at Integrous Big Hearts, Big Ideas Virtual Investor Conference

Autonomix Medical, Inc. Receives Ethics Committee Authorization for Proof-of-Concept Human Clinical Study Evaluating Proprietary Ablation Technology for Treatment of Pancreatic Cancer Pain

GlobeNewswire

a year ago

Autonomix Medical, Inc. Receives Ethics Committee Authorization for Proof-of-Concept Human Clinical Study Evaluating Proprietary Ablation Technology for Treatment of Pancreatic Cancer Pain

Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event

GlobeNewswire

a year ago

Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event

Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024

GlobeNewswire

a year ago

Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024

Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio

GlobeNewswire

a year ago

Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio

Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use

GlobeNewswire

a year ago

Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use

Autonomix Medical, Inc. (NASDAQ: AMIX) Commences Trading on NASDAQ

GlobeNewswire

a year ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Commences Trading on NASDAQ

Share on Social Networks: